Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study
Abstract Background The development and approval of disease modifying treatments have dramatically changed disease progression in patients with spinal muscular atrophy (SMA). Nusinersen was approved in Europe in 2017 for the treatment of SMA patients irrespective of age and disease severity. Most da...
Similar Items
-
Factors affecting the implementation of the SmartCare EHR system in Zambia
by: Paul Chabala Kaumba
Published: (2023-01-01) -
A post-market cluster randomized controlled trial of the effect of the TENA SmartCare Change Indicator™ on urinary continence care efficiency and skin health in older nursing home residents
by: Muyibat Omotunde, et al.
Published: (2023-02-01) -
High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophy
by: Jessika Johannsen, et al.
Published: (2023-11-01) -
Expanding the phenotype of RBCK1-associated polyglucosan body myopathy type 1
by: Manuel Pühringer, et al.
Published: (2024-03-01) -
Corrigendum to “Expanding the phenotype of RBCK1-associated polyglucosan body myopathy type 1”
by: Manuel Pühringer, et al.
Published: (2024-03-01)